Latest news with #TempusAI
Yahoo
2 hours ago
- Business
- Yahoo
Tempus AI (TEM) Raises 2025 Earnings Guidance Amid US$500 Million Equity Offering
Tempus AI has recently been in the spotlight after raising its earnings guidance and reporting a substantial improvement in its financial results for Q2 2025, with revenue jumping from a year ago and a significant reduction in net losses. The company's decision to pursue a $500 million equity offering reflects its confidence in growth prospects. Over the past week, Tempus AI's share price increased 11%, aligning with the tech sector's overall positive trends. With the Nasdaq reaching a record high led by a tech stock rally, Tempus AI's stock move complements this broader market surge. We've identified 3 warning signs with Tempus AI and understanding the impact should be part of your investment process. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource. The recent announcement by Tempus AI (TEM) regarding their earnings guidance and Q2 2025 financial performance underscores the company's strong momentum. This positive news, coupled with an 11% rise in share price over the past week, is likely to bolster investor confidence. Analysts' revenue projections and the company's strategic partnerships suggest a focus on sustainable, high-margin growth. Notably, Tempus AI's total shareholder return over the last year was 57.08%, reflecting significant long-term shareholder value creation. Within the life sciences sector, Tempus AI outperformed the industry's previous year return of -23.1%, evidencing robust market positioning. The current share price of US$60.87 shows an 11.22% discount to the consensus price target of US$67.7. If recent strategic initiatives lead to higher future earnings, Tempus AI could draw closer to this target, though profitability is still not projected in the near term. Revenue forecasts indicate strong growth potential, with a 17.5% annual increase expected, surpassing US market growth rates. This aligns with the company's moves to secure data-driven precision medicine partnerships. Nonetheless, challenges such as reliance on large pharma partnerships and data privacy issues remain, which could impact longer-term earnings visibility. Investors are advised to consider these factors when evaluating the stock's potential. Our valuation report here indicates Tempus AI may be overvalued. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
20 hours ago
- Business
- Yahoo
Why Tempus AI Stock Jumped Today
Key Points Tempus AI beat Wall Street's sales and earnings targets in the second quarter. The company posted a big sales beat in the second quarter, and management increased the company's full-year sales target. Tempus AI also looks poised to record a big improvement this year. 10 stocks we like better than Tempus AI › The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended the daily session solidly in the green. The healthcare artificial intelligence (AI) company's share price ended Friday's trading up 3.6% but had been up 11.9% earlier in the session. Tempus AI delivered its second-quarter report before the market opened this morning, and sales and earnings for the period topped Wall Street's expectations. In addition to performance beats in the quarter, the company raised its full-year sales guidance. Tempus AI stock rose on the strength of Q2 sales momentum The company saw an adjusted loss of $0.22 per share on revenue of $314.6 million in the second quarter. The average Wall Street analyst estimate had targeted an adjusted per-share loss of $0.25 on sales of roughly $297.8 million. Sales increased roughly 90% year over year and far surpassed Wall Street's expectations, with strong momentum for the company's genomics segment powering huge growth. The stock gave back some of its early gains as today's trading progressed, but the healthcare AI software specialist delivered a strong quarterly report. What's next for Tempus AI? In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this year. The company now expects full-year revenue to come in at roughly $1.26 billion, up from its previous target for sales of $1.26 billion. The new target suggests annual sales growth of roughly 86%. The company also said that it anticipates posting adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $5 million this year -- representing a $110 million improvement over last year's performance. With strong sales growth and signs of improving margins, Tempus AI could be on track to deliver strong results for long-term shareholders. Should you buy stock in Tempus AI right now? Before you buy stock in Tempus AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Tempus AI Stock Jumped Today was originally published by The Motley Fool
Yahoo
a day ago
- Business
- Yahoo
Gold hits new high, altcoins stocks rally, Tempus AI Q2 beat
Yahoo Finance anchor Julie Hyman tracks Friday's top moving stocks and biggest market stories in this Market Minute. Gold (GC=F) futures hit new highs after the US confirmed President Trump's reciprocal tariffs apply to one-kilogram gold bar imports. Ethereum (ETH-USD) and altcoins rally on news that Ripple (XRP-USD) will acquire stablecoin payments platform Rail. Tempus AI (TEM) stock rises after the company topped second quarter estimates and raised its full-year outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's market minute. Stocks are rising to close out a busy week. The S&P 500 and Nasdaq eyeing fresh record highs as investors digest the latest tariff news, plus earnings. Gold futures are hitting a new high on news that the precious metal is not exempt from tariffs. US Customs confirming that President Trump's reciprocal tariffs are imposed on imports of 1 kilogram gold bars. This will affect key refining hubs like Switzerland and Hong Kong. And remember, Switzerland has already been hit with that big 39% tariff. Ethereum and altcoins are rallying on news that Ripple is buying stable coin payments platform Rail in a $200 million deal. Meanwhile, the altcoin Chainlink is launching a reserve of its own tokens. And Tempus AI topping Wall Street's estimates in its second quarter and raising its full-year guidance. The health tech company citing accelerating growth in its cancer and genetic testing units. And that's your Yahoo! Finance market minute. Related Videos S&P 500 has a concentration problem: Why ETFs can't keep up Trade Desk nosedives, Twilio weak outlook, FuboTV revenue beat Serve Robotics CEO: Drones are 'complementary,' not competitive SoundHound AI CEO talks Q2 beat as stock skyrockets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.35%. A quarter ago, it was expected that this health care technology company would post a loss of $0.27 per share when it actually produced a loss of $0.24, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Tempus, which belongs to the Zacks Medical Info Systems industry, posted revenues of $314.64 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.12%. This compares to year-ago revenues of $165.97 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tempus shares have added about 74% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for Tempus? While Tempus has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Tempus was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.18 on $325.52 million in revenues for the coming quarter and -$0.67 on $1.24 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Phreesia (PHR), is yet to report results for the quarter ended July 2025. This developer of health care software is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +77.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $116.45 million, up 14% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tempus AI, Inc. (TEM) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
a day ago
- Business
- Yahoo
Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins
Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. View more earnings on TEM 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,' Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next:Photo by Piotr Swat via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
